loading

Kala Bio Inc 주식(KALA)의 최신 뉴스

pulisher
07:11 AM

Is KALA BIO Inc. a good long term investmentHigh-velocity gains - PrintWeekIndia

07:11 AM
pulisher
02:58 AM

KALA BIO Inc. Stock Analysis and ForecastPhenomenal wealth increase - PrintWeekIndia

02:58 AM
pulisher
Jul 24, 2025

Should I buy KALA BIO Inc. stock before earningsHigh-performance investment picks - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about KALA BIO Inc. stockTremendous gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives KALA BIO Inc. stock priceOutstanding risk-reward balance - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Stellantis N.V. stockRemarkable growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is CURR a good long term investmentDynamic investment growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

KALA BIO (NASDAQ:KALA) Downgraded to “Sell” Rating by Wall Street Zen - Defense World

Jul 20, 2025
pulisher
Jul 15, 2025

What makes KALA BIO Inc. stock price move sharplyHigh Return Conservative Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why KALA BIO Inc. stock attracts strong analyst attentionMomentum Buy Alert - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How KALA BIO Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

All Eyes On KALA's CHASEWill The PCED Trial Make Its Case? - RTTNews

Jul 14, 2025
pulisher
Jul 14, 2025

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times

Jul 14, 2025
pulisher
Jul 13, 2025

LADENBURG THALM/SH SH Initiates Coverage on KALA BIO (NASDAQ:KALA) - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

KALA Bio completes enrollment of CHASE clinical trial - Ophthalmology Times

Jul 12, 2025
pulisher
Jul 12, 2025

KALA BIO (NASDAQ:KALA) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Jul 11, 2025
pulisher
Jul 11, 2025

Ladenburg Thalmann Initiates KALA BIO at Buy With $12 Price Target - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg | KALA Stock News - GuruFocus

Jul 11, 2025
pulisher
Jul 10, 2025

Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg - GuruFocus

Jul 10, 2025
pulisher
Jul 09, 2025

Kala Bio Announces Completion of Enrollment in Chase Clinical Trial Evaluating Kpi-012 for the Treatment of Persistent Corneal Epithelial Defect - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

KALA Completes Patient Enrollment in Phase 2b CHASE Trial for KP - GuruFocus

Jul 09, 2025
pulisher
Jul 09, 2025

Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

Kala Bio completes enrollment in Phase 2b trial for KPI-012 in eye disorder - Investing.com

Jul 09, 2025
pulisher
Jul 09, 2025

KALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial for KPI-012, Anticipates Topline Results by Q3 2025 - Quiver Quantitative

Jul 09, 2025
pulisher
Jul 09, 2025

KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire

Jul 09, 2025
pulisher
Jul 09, 2025

KALA BIO Eyes 100,000 Patient Market as Pivotal PCED Trial Completes Enrollment, Q3 Results Ahead - Stock Titan

Jul 09, 2025
pulisher
Jul 07, 2025

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discu - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - Yahoo Finance

Jul 07, 2025
pulisher
Jun 26, 2025

KALA BIO Executives Sell Shares Under 10b5-1 Plans - TradingView

Jun 26, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Purchases 17,130 Shares of HBT Financial, Inc. (NASDAQ:HBT) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Decreases Stake in KALA BIO, Inc. (NASDAQ:KALA) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Nexa Resources S.A. (NYSE:NEXA) Shares Sold by Millennium Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

24,353 Shares in T. Rowe Price Floating Rate ETF (NYSEARCA:TFLR) Acquired by Bank of America Corp DE - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Cadre Holdings, Inc. (NYSE:CDRE) Shares Acquired by Millennium Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Acquires 2,612 Shares of First Trust Indxx Global Natural Resources Income ETF (NASDAQ:FTRI) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Sells 1,791 Shares of Bluerock Homes Trust, Inc. (NYSEAMERICAN:BHM) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Buys 11,012 Shares of Liberty All-Star Growth Fund, Inc. (NYSE:ASG) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Kala Bio director Mark Iwicki sells $40,638 in stock By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Kala Bio director Mark Iwicki sells $40,638 in stock - Investing.com India

Jun 05, 2025
$23.29
price down icon 1.74%
$36.50
price up icon 0.00%
$103.56
price down icon 0.03%
$27.38
price down icon 0.69%
$113.86
price down icon 0.68%
biotechnology ONC
$288.37
price down icon 2.39%
자본화:     |  볼륨(24시간):